A Randomized Phase II Trial to Evaluate an EBV Derived Dendritic Cell (DC) Vaccine When Administered Alone or Co-administered With the TLR9 Agonist, DUK-CPG-001, in EBV+ Lymphoma in the Setting of Autologous Stem Cell Transplant

This is a non-blinded, not placebo controlled, randomized, parallel phase 2 pilot study to evaluate the immunological response and the safety of Epstein Barr Virus (EBV)-derived tumor antigen, Latent Membrane Protein-2 (LMP2)-loaded dendritic cell (DC) vaccines alone or co-administered with the TLR9 ligand, DUK-CPG-001, in patients with EBV+ lymphoma in the setting of autologous stem cell transplant with infusion of mature T cells. Patients will be randomized to receive vaccine alone or vaccine co-administered with the TLR9 ligand, DUK-CPG-001. Randomization will be stratified by 2 disease types: Hodgkin lymphoma and non-Hodgkin lymphoma.

Start Date01 Dec 2016

Sponsor / Collaborator

Duke University

NCT02452697 / Active, not recruitingPhase 2IIT

A Randomized Phase II Trial to Evaluate Progression-Free Survival Rates in Patients Receiving NK Cell-Enriched Donor Cell Infusions When Administered Alone or Administered With the TLR9 Agonist, DUK-CPG-001, From a 4-6/8 HLA-Matched Related or 7-8/8 HLA-Matched Donor Following Reduced Intensity or Non-Ablative Allogeneic Stem Cell Transplantation

This is a randomized, parallel phase II study to evaluate the rates of progression-free survival and unacceptable toxicity in patients receiving NK cell-enriched donor lymphocyte infusions (DLIs) when administered alone or administered with the TLR9 agonist, DUK-CPG-001, from a 7-8/8 HLA-matched related or unrelated donor (Cohort A) or 4-6/8 HLA-matched related donor (Cohort B) following reduced intensity or non-ablative allogeneic stem cell transplantation. Randomization will be stratified for disease types (myeloid versus lymphoid malignancies). Primary endpoints are analyzed separately in Cohort A and B.
Cohort A: 7-8/8 HLA-matched related or unrelated donor ("NK cell enriched-DLI only" arm or "NK cell enriched-DLI + DUK-CPG-001" arm)
Cohort B: 4-6/8 HLA-matched related donor ("NK cell enriched-DLI only" arm or "NK cell enriched-DLI + DUK-CPG-001" arm)

Start Date08 Jun 2016

Sponsor / Collaborator

Duke University

[+1]

100 Clinical Results associated with DUK-CPG-001

100 Translational Medicine associated with DUK-CPG-001

100 Patents (Medical) associated with DUK-CPG-001

100 Deals associated with DUK-CPG-001

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Lymphoma	Phase 2	US	Agilent Technologies, Inc.	08 Jun 2016
Myeloid Tumor	Phase 2	US	Agilent Technologies, Inc.	08 Jun 2016
Acute Graft Versus Host Disease	Phase 1	US	Agilent Technologies, Inc. /X-Ray Diffraction Business/	08 Jun 2016
Epstein-Barr Virus-Related Lymphoma	Discovery	US	Duke University	01 Dec 2016
Hodgkin's Lymphoma	Discovery	US	Duke University	01 Dec 2016
Non-Hodgkin Lymphoma	Discovery	US	Duke University	01 Dec 2016
Brain Cancer	Discovery	US	Duke University	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02452697 (NK-DCI, CTgov)	Phase 2	Myeloid Tumor \| Lymphoma	36	NK Cell enriched-DLI only (Cohort A - NK Cell Enriched-DLI Only)	xpcznbhhpk(ornqhdjprl) = sizgxfdqeu nfmutyncai (kbftqazgkz, mshiafdokc - wenbduimpq) View more	-	20 Feb 2024
				DUK-CPG-001 (Cohort A - NK-DLI + DUK-CPG-001)	xpcznbhhpk(ornqhdjprl) = jwnwburgig nfmutyncai (kbftqazgkz, sdbglwvsgj - xiwatyqjrw) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis